Success Metrics

Active Trials

4(31%)

Phase Distribution

Ph early_phase_1

54%

Ph phase_1

46%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Early Phase 1First-in-human

7(53.8%)

Phase 1Safety & dosage

6(46.2%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(6)

Terminated(1)

Other(6)

Detailed Status

unknown6

Recruiting4

Not yet recruiting2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Early Phase 17 (53.8%)

Phase 16 (46.2%)

Trials by Status

withdrawn18%

unknown646%

not_yet_recruiting215%

recruiting431%

Recent Activity

4 active trials

Showing 5 of 13

recruitingphase_1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

NCT07250269

recruitingphase_1

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

NCT06530849

recruitingearly_phase_1

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

NCT07058298

not_yet_recruitingearly_phase_1

GC012F in Patients With Autoimmune Diseases

NCT07072884

withdrawnearly_phase_1

An Exploratory Clinical Study of GC012F Injection for Refractory gMG

NCT06419166

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT07250269Phase 1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Recruiting

NCT06530849Phase 1

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Recruiting

NCT07058298Early Phase 1

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Recruiting

NCT07072884Early Phase 1

GC012F in Patients With Autoimmune Diseases

Not Yet Recruiting

NCT06419166Early Phase 1

An Exploratory Clinical Study of GC012F Injection for Refractory gMG

Withdrawn

NCT06759948Phase 1

An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

Not Yet Recruiting

NCT05840107Early Phase 1

Study of FasT CAR-T GC012F Injection NDMM Patients

Recruiting

NCT05858684Early Phase 1

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Unknown

NCT05846347Phase 1

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

Unknown

NCT04935580Phase 1

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Unknown

NCT05412329Phase 1

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Unknown

NCT04617704Early Phase 1

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Unknown

NCT04236011Early Phase 1

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Unknown

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13